108 related articles for article (PubMed ID: 25266204)
1. O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells.
Fathallah AM; Ramakrishnan R; Balu-Iyer SV
J Pharm Sci; 2014 Nov; 103(11):3457-3463. PubMed ID: 25266204
[TBL] [Abstract][Full Text] [Related]
2. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
Gaitonde P; Purohit VS; Balu-Iyer SV
Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
[TBL] [Abstract][Full Text] [Related]
3. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
4. Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.
Ramakrishnan R; Balu-Iyer SV
J Pharm Sci; 2016 Oct; 105(10):3039-3045. PubMed ID: 27431011
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII.
Gaitonde P; Peng A; Straubinger RM; Bankert RB; Balu-Iyer SV
J Pharm Sci; 2012 Jan; 101(1):48-55. PubMed ID: 21953409
[TBL] [Abstract][Full Text] [Related]
6. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
8. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
Miclea RD; Purohit VS; Balu-Iyer SV
AAPS J; 2007 Jun; 9(2):E251-9. PubMed ID: 17907766
[TBL] [Abstract][Full Text] [Related]
9. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.
Gaitonde P; Peng A; Straubinger RM; Bankert RB; Balu-Iyer SV
Clin Immunol; 2011 Feb; 138(2):135-45. PubMed ID: 21094627
[TBL] [Abstract][Full Text] [Related]
11. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
12. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice.
Gaitonde P; Ramakrishnan R; Chin J; Kelleher RJ; Bankert RB; Balu-Iyer SV
J Biol Chem; 2013 Jun; 288(24):17051-6. PubMed ID: 23649621
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells.
Qadura M; Othman M; Waters B; Chegeni R; Walker K; Labelle A; Ozelo M; Hough C; Lillicrap D
J Thromb Haemost; 2008 Dec; 6(12):2095-104. PubMed ID: 18826393
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
15. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
[TBL] [Abstract][Full Text] [Related]
16. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10.
Oliveira VG; Agua-Doce A; Curotto de Lafaille MA; Lafaille JJ; Graca L
Blood; 2013 May; 121(19):3936-45, S1. PubMed ID: 23532736
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice.
Sule G; Suzuki M; Guse K; Cela R; Rodgers JR; Lee B
Hum Gene Ther; 2012 Jul; 23(7):769-80. PubMed ID: 22468961
[TBL] [Abstract][Full Text] [Related]
19. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.
Hartholt RB; Wroblewska A; Herczenik E; Peyron I; Ten Brinke A; Rispens T; Nolte MA; Slot E; Claassens JW; Nimmerjahn F; Verbeek JS; Voorberg J
J Thromb Haemost; 2017 Feb; 15(2):329-340. PubMed ID: 27868337
[TBL] [Abstract][Full Text] [Related]
20. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
